As of June 2022, Iconic Therapeutics is a wholly owned subsidiary of Endpoint Health

for more information

to learn more about Endpoint Health

TF in Inflammation

Central modulation of cytokines and an ideal target for treating acute and chronic inflammatory conditions, such as acute lung injury, vasculitis, anti-phospholipid syndrome and inflammatory bowel disease.

LEARN MORE

TF in Ophthalmology

Promising opportunities to treat serious diseases in ophthalmology, including age-related macular degeneration (AMD) and diabetic retinopathy.

LEARN MORE

TF in Oncologyncology

Overexpression facilitates key oncogenic processes that lead to the development and progression of tumors. Iconic`s oncology program is partnered with Exelixis.

LEARN MORE
Share by: